Immunomedics Inc. (NASDAQ:IMMU) shares traded down 7.7% on Monday . The company traded as low as $2.27 and last traded at $2.29, with a volume of 874,065 shares trading hands. The stock had previously closed at $2.48.

A number of research analysts have weighed in on the company. Wells Fargo & Co. restated a “buy” rating on shares of Immunomedics in a report on Tuesday, May 24th. Jefferies Group restated a “buy” rating and issued a $5.00 price objective on shares of Immunomedics in a report on Monday, June 6th. Finally, Zacks Investment Research lowered Immunomedics from a “buy” rating to a “sell” rating in a report on Tuesday, May 10th.

The company’s market cap is $209.52 million. The company has a 50-day moving average of $3.14 and a 200-day moving average of $2.79.

Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.02. Equities research analysts expect that Immunomedics Inc. will post ($0.57) earnings per share for the current year.

In related news, Chairman David M. Goldenberg sold 353,010 shares of the company’s stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $3.88, for a total transaction of $1,369,678.80. Following the transaction, the chairman now owns 2,602,063 shares of the company’s stock, valued at $10,096,004.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Cynthia L. Goldenberg sold 63,959 shares of the company’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $4.09, for a total value of $261,592.31. Following the transaction, the chief executive officer now directly owns 703,029 shares in the company, valued at approximately $2,875,388.61. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Immunomedics stock. Marshall Wace LLP acquired a new position in Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned about 0.90% of Immunomedics as of its most recent SEC filing.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.